Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | MAP2 | P11137 | 2/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214330 | 0.76 | KDM4E (0.56) | MAPK1SMN1; SMN2 | |
| SCHEMBL5066580 | 0.75 | NPSR1 (0.44) | MAPK1MAP2 | |
| SCHEMBL5117028 | 0.75 | NGFR (0.40) | SMN1; SMN2CA2CA1MAP2 | |
| SCHEMBL5773017 | 0.74 | KDM4E (0.34) | MAP2CXCR2 | |
| SCHEMBL7213100 | 0.71 | KDM4E (0.57) | MAPK1SMN1; SMN2PTPN11 | |
| SCHEMBL2983431 | 0.71 | MAP2 (0.51) | MAP2 | |
| SCHEMBL7208144 | 0.70 | KDM4E (0.41) | MAPK1SMN1; SMN2EPHX2 | |
| SCHEMBL7208205 | 0.70 | ALDH1A1 (0.56) | SMN1; SMN2 | |
| SCHEMBL7637344 | 0.68 | NQO2 (0.43) | MAPK1SMN1; SMN2 | |
| SCHEMBL7213103 | 0.67 | KDM4E (0.41) | MAPK1SMN1; SMN2PTPN1EPHX2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | MAPK1 2933/4885SMN1; SMN2 3730/4885CA2 3267/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | MAPK1 1632/4885SMN1; SMN2 4386/4885CA2 4102/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | MAPK1 2933/4885SMN1; SMN2 3730/4885CA2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.